Search results for " criteri"

showing 10 items of 545 documents

Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: Joint analysis of MILES-3 and MILES-4 phase III tr…

2018

Purpose To test the efficacy of adding cisplatin to first-line treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC) within a combined analysis of two parallel phase III trials, MILES-3 and MILES-4. Patients and Methods Patients with advanced NSCLC who were older than age 70 years with Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned to gemcitabine or pemetrexed, without or with cisplatin. In each trial, 382 events were required to detect a hazard ratio (HR) of death of 0.75, with 80% power and two-tailed α of .05. Trials were closed prematurely because of slow accrual, but the joint database allowed us to analyze the efficacy of …

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyPhases of clinical researchKaplan-Meier EstimatePemetrexedDeoxycytidine03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell Lungmedicineadvanced non small cell lung cancer (NSCLC) elderly patients cisplatin MILES 3 MILES 4Progression-free survivalLung cancerSurvival rateAgedAged 80 and overAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industrymedicine.diseaseGemcitabineLung Neoplasm030104 developmental biologyPemetrexedTreatment OutcomeOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisQuality of LifeFemaleCisplatinbusinessmedicine.drugHuman
researchProduct

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highli…

2017

Abstract Background Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. Material and methods Two dedifferentiated-SFT (D-SFT) models obtained from patients' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were tr…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_treatmentSolitary fibrous tumourSoft Tissue NeoplasmsDioxoleMice SCIDPharmacologyAnthracyclineMetastasichemistry.chemical_compound0302 clinical medicineSolitary Fibrous TumorRetrospective StudieTetrahydroisoquinolinesAntineoplastic Combined Chemotherapy ProtocolsTetrahydroisoquinolineMeningeal NeoplasmsMeningeal NeoplasmPleural NeoplasmTrabectedinIfosfamideKidney NeoplasmSarcomaKetonesMiddle AgedMice modelKetoneKidney NeoplasmsDacarbazineSurvival RateOncologyResponse Evaluation Criteria in Solid TumorsSolitary Fibrous Tumors030220 oncology & carcinogenesisFemalemedicine.drugEribulinHumanAdultmedicine.medical_specialtyXenograft Model Antitumor AssayAnthracyclinePleural NeoplasmsDacarbazineBlotting WesternResponse Evaluation Criteria in Solid TumorDioxolesDisease-Free Survival03 medical and health sciencesInternal medicinemedicineAnimalsHumansChemotherapyFuranDoxorubicinRetroperitoneal NeoplasmsEribulinIfosfamideSoft Tissue NeoplasmCerebellar NeoplasmsFuransResponse Evaluation Criteria in Solid TumorsRetrospective StudiesAgedChemotherapyAntineoplastic Combined Chemotherapy ProtocolRetroperitoneal Neoplasmbusiness.industryAnimalXenograftCerebellar NeoplasmXenograft Model Antitumor AssaysTreatment030104 developmental biologychemistryDoxorubicinbusinessTrabectedin
researchProduct

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

2016

// Francesco Passiglia 1, * , Giuseppe Bronte 1, * , Viviana Bazan 1, * , Clara Natoli 2 , Sergio Rizzo 1 , Antonio Galvano 1 , Angela Listi 1 , Giuseppe Cicero 1 , Christian Rolfo 3 , Daniele Santini 4 , Antonio Russo 1 1 Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 2 Department of Medical, Oral and Biotechnological Sciences, University “G. D’Annunzio”, Chieti, Italy 3 Phase I- Early Clinical Trials Unit, Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium 4 Medical Oncology Department, Campus Biomedico, University of Rome, Rome, Italy * These auth…

0301 basic medicineOncologyPD-L1medicine.medical_specialtyLung NeoplasmsAnti-PD1/PD-L1 MoAbsmedicine.medical_treatmentAnti-PD1/PD-L1 MoAbAntineoplastic AgentsCochrane LibraryNSCLCB7-H1 Antigen03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungPD-L1Internal medicineOutcome Assessment Health CareBiomarkers TumorOdds RatioHumansMedicineLung cancerBiologybiologybusiness.industryAntibodies MonoclonalImmunotherapyOdds ratioPrognosismedicine.diseaseAnti-PD1/PD-L1 MoAbs; Immunotherapy; NSCLC; PD-L1; Predictive biomarker; OncologyImmunohistochemistryClinical trialPredictive biomarker030104 developmental biologyClinical trials unitOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisImmunologybiology.proteinHuman medicineImmunotherapybusinessResearch Paper
researchProduct

Physical fitness assessment in Goalball: A scoping review of the literature

2020

Background Goalball is a Paralympic sport for visually impaired athletes. Although it is widely practiced, a great variety of tests are adopted to evaluate athletes' physical fitness. Therefore, the objective was to identify the physical fitness tests adopted in this sport to find the common aspects between them and, eventually, to propose a standard operating procedure. Methods The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines were adopted. The studies were extracted from PubMed, Web of Science, and Scopus. A selection process by title, abstract, and full-text, according to the inclusion and exclusion criteria, was …

0301 basic medicineQuality of lifePhysical fitnessApplied psychologyScopusArticle03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Aging and life courseVisually impaired peoplelcsh:Social sciences (General)lcsh:Science (General)Public healthMultidisciplinaryDisabilitybiologyAthletesbusiness.industryPhysical activitybiology.organism_classificationTest (assessment)030104 developmental biologySystematic reviewHealth-related evaluationInclusion and exclusion criterialcsh:H1-99Aging and life course Disability Health-related evaluation Physical activity Public health Quality of life Standard operating procedure Visually impaired peoplePsychologybusinessStandard operating procedure030217 neurology & neurosurgeryStandard operating procedurelcsh:Q1-390Heliyon
researchProduct

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or me…

2020

Background Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in advanced colorectal or squamous cell head and neck cancers. With prospective serum and tumour biomarkers, we tested if P added to CF (CFP) improved OS in advanced ESCC. Patients and methods Eligible patients with confirmed ESCC that was not curatively resectable or did not qualify for definitive radiochemotherapy, were randomised 1 : 1 to receive CF [cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1–4] or CF plus P (9…

0301 basic medicinemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentPopulationMedizinGastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicinePanitumumabHumansProspective StudieseducationCisplatineducation.field_of_studyChemotherapybusiness.industryPanitumumabHazard ratioCommon Terminology Criteria for Adverse EventsHematologymedicine.diseaseErbB Receptors030104 developmental biologyTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisCarcinoma Squamous CellFluorouracilCisplatinbusinessProgressive diseasemedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

2021

BACKGROUND AND AIMS: Electronic health record (EHR)-based research allows the capture of large amounts of data, which is necessary in nonalcoholic fatty liver disease (NAFLD), where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Disease (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues.APPROACH AND RESULTS: Researchers with an interest in EHR-based NAFLD research were invited to collect…

0301 basic medicinemedicine.medical_specialtyFIBROSIS STAGEBiomedical ResearchConsensusClinical SciencesImmunologyDiseaseMedical Biochemistry and MetabolomicsDIAGNOSISVALIDATIONArticle03 medical and health sciences0302 clinical medicineClinical ResearchNon-alcoholic Fatty Liver DiseaseEpidemiologyHealth caremedicineElectronic Health RecordsHumansGeneralizability theoryALGORITHMFATTY LIVER-DISEASEStatement (computer science)Gastroenterology & HepatologyHepatologybusiness.industryMORTALITYComparabilityClinical CodingReference Standards3. Good healthGood Health and Well Being030104 developmental biology3121 General medicine internal medicine and other clinical medicineFamily medicineInclusion and exclusion criteria030211 gastroenterology & hepatologyPatient SafetybusinessPsychologyREAL-WORLDCoding (social sciences)Hepatology
researchProduct

Membrane Attack Complex in Myocardial Ischemia/Reperfusion Injury: A Systematic Review for Post Mortem Applications

2020

The complement system has a significant role in myocardial ischemia/reperfusion injury, being responsible for cell lysis and amplification of inflammatory response. In this context, several studies highlight that terminal complement complex C5b-9, also known as the membrane attack complex (MAC), is a significant contributor. The MAC functions were studied by many researchers analyzing the characteristics of its activation in myocardial infarction. Here, a systematic literature review was reported to evaluate the principal features, advantages, and limits (regarding the application) of complement components and MAC in post mortem settings to perform the diagnosis of myocardial ischemia/infar…

0301 basic medicinemedicine.medical_specialtyForensic pathologyClinical BiochemistryInfarctionContext (language use)Reviewischemia/reperfusion injury03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleInternal medicinemedicine030216 legal & forensic medicineMyocardial infarctioncomplement systemlcsh:R5-920business.industryC5b-9schemia/reperfusion injuryforensic pathologymedicine.diseaseComplement systempost mortem investigation030104 developmental biologymyocardial infarctionInclusion and exclusion criteriaCardiologyC5b-9; complement system; forensic pathology; ischemia/reperfusion injury; myocardial infarction; post mortem investigationbusinessComplement membrane attack complexlcsh:Medicine (General)Reperfusion injury
researchProduct

Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease.

2018

The diagnosis of Parkinson’s disease (PD) is based on clinical features and differently to the common opinion that detecting this condition is easy, seminal clinico-pathological studies have shown that up one-fourth of patients diagnosed as PD during life has an alternative diagnosis at post-mortem. The misdiagnosis is even higher when only the initial diagnosis is considered, since the diagnostic accuracy improves by time, during follow-up visits. Given that the confirmation of the diagnosis of PD can be only obtained through neuropathology, to improve and facilitate the diagnostic-therapeutic workup in PD, a number of criteria and guidelines have been introduced in the last three decades.…

0301 basic medicinemedicine.medical_specialtyParkinson's disease diagnostic criteriapreclinical Parkinson’s diseaseParkinson's diseaseParkinson’s disease guidelinesNeuropathologyDiseaseReviewlcsh:RC346-429prodromal Parkinson’s disease03 medical and health sciences0302 clinical medicinePreclinical Parkinson's diseasemedicineProdromal Parkinson's diseaseIntensive care medicinelcsh:Neurology. Diseases of the nervous systemJames Parkinsonbusiness.industryTask forceNoveltymedicine.diseaseClinical trial030104 developmental biologyNeurologyClinical diagnosisParkinson's disease guidelineParkinson’s disease diagnostic criteriaNeurology (clinical)Early phasebusiness030217 neurology & neurosurgeryNeuroscienceFrontiers in neurology
researchProduct

2018

There are two important gaps of knowledge in depression treatment, namely the lack of biomarkers predicting response to antidepressants and the limited knowledge of the molecular mechanisms underlying clinical improvement. However, individually tailored treatment strategies and individualized prescription are greatly needed given the huge socio-economic burden of depression, the latency until clinical improvement can be observed and the response variability to a particular compound. Still, individual patient-level antidepressant treatment outcomes are highly unpredictable. In contrast to other therapeutic areas and despite tremendous efforts during the past years, the genomics era so far ha…

0301 basic medicinemedicine.medical_specialtyTreatment responsebusiness.industryTranslational medicineTranslational researchTailored treatmentResponse Variability03 medical and health sciencesPsychiatry and Mental health030104 developmental biology0302 clinical medicinemedicineAntidepressantIntensive care medicinebusiness030217 neurology & neurosurgeryDepression (differential diagnoses)Research Domain CriteriaFrontiers in Psychiatry
researchProduct

Multi-criteria analysis applied to multi-objective optimal pump scheduling in water systems

2019

Abstract This work presents a multi-criteria-based approach to automatically select specific non-dominated solutions from a Pareto front previously obtained using multi-objective optimization to find optimal solutions for pump control in a water supply system. Optimal operation of pumps in these utilities is paramount to enable water companies to achieve energy efficiency in their systems. The Fuzzy Technique for Order of Preference by Similarity to Ideal Solution (FTOPSIS) is used to rank the Pareto solutions found by the non-dominated sorting genetic algorithm (NSGA-II) employed to solve the multi-objective problem. Various scenarios are evaluated under leakage uncertainty conditions, res…

050210 logistics & transportationMathematical optimizationMulti-criteria analysisWater distribution systemsComputer science0208 environmental biotechnology05 social sciencesScheduling (production processes)02 engineering and technologyMulti-objective optimization020801 environmental engineeringMulti-objective optimizationMulti criteria0502 economics and businessSettore ING-IND/17 - Impianti Industriali MeccaniciOptimal pump schedulingMATEMATICA APLICADAWater Science and Technology
researchProduct